Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL. Kanjanapan Y, et al. Among authors: razak aa. Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15. Cancer. 2019. PMID: 30768786 Free article.
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry.
Music M, Iafolla M, Soosaipillai A, Batruch I, Prassas I, Pintilie M, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Siu LL, Diamandis EP. Music M, et al. Among authors: razak aa. F1000Res. 2020 May 7;9:337. doi: 10.12688/f1000research.22715.1. eCollection 2020. F1000Res. 2020. PMID: 33299547 Free PMC article. Clinical Trial.
Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy.
Araujo DV, Wang A, Torti D, Leon A, Marsh K, McCarthy A, Berman H, Spreafico A, Hansen AR, Razak AA, Bedard PL, Wang L, Plackmann E, Chow H, Bao H, Wu X, Pugh TJ, Siu LL. Araujo DV, et al. Among authors: razak aa. JNCI Cancer Spectr. 2021 Jan 23;5(3):pkaa122. doi: 10.1093/jncics/pkaa122. eCollection 2021 Jun. JNCI Cancer Spectr. 2021. PMID: 34056539 Free PMC article.
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
George S, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon MS, Somaiah N, Jennings J, Meade J, Shi K, Su Y, Ruiz-Soto R, Janku F. George S, et al. Among authors: razak aa. Eur J Cancer. 2021 Sep;155:236-244. doi: 10.1016/j.ejca.2021.07.010. Epub 2021 Aug 12. Eur J Cancer. 2021. PMID: 34391056 Free PMC article.
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi H, Aleshin A, Torti D, Marsh K, Eagles J, Cirlan I, Hanna Y, Clouthier DL, Lien SC, Ohashi PS, Xu W, Siu LL, Pugh TJ. Bratman SV, et al. Among authors: razak aa. Nat Cancer. 2020 Sep;1(9):873-881. doi: 10.1038/s43018-020-0096-5. Epub 2020 Aug 3. Nat Cancer. 2020. PMID: 35121950
Real-world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study.
Peretz Soroka H, Vora T, Noujaim J, Marcoux N, Cohen-Gogo S, Alcindor T, Holloway C, Rodrigues C, Karachiwala H, Alvi S, Lee U, Cheng S, Banerji S, Oberoi S, Feng X, Smrke A, Simmons C, Razak AA, Gupta AA. Peretz Soroka H, et al. Among authors: razak aa. Cancer Med. 2023 Sep;12(18):18872-18881. doi: 10.1002/cam4.6515. Epub 2023 Sep 19. Cancer Med. 2023. PMID: 37724607 Free PMC article.
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.
Hernando-Calvo A, Yang SYC, Vila-Casadesús M, Han M, Liu ZA, Berman AHK, Spreafico A, Razak AA, Lheureux S, Hansen AR, Lo Giacco D, Abbas-Aghababazadeh F, Matito J, Haibe-Kains B, Pugh TJ, Bratman SV, Aleshin A, Berche R, Saavedra O, Garralda E, Elston S, Siu LL, Ohashi PS, Vivancos A, Bedard PL. Hernando-Calvo A, et al. Among authors: razak aa. JCO Precis Oncol. 2024 Aug;8:e2400100. doi: 10.1200/PO.24.00100. JCO Precis Oncol. 2024. PMID: 39178369 Free PMC article. Clinical Trial.
First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies.
Kummar S, Razak AA, Laurie S, Glatt DM, Kell S, Diep AN, Schmidt M, Hom C, German C, Shringarpure SS, Majeed SR, Rasco D. Kummar S, et al. Among authors: razak aa. Cancer Res Commun. 2025 Jan 1;5(1):94-105. doi: 10.1158/2767-9764.CRC-24-0568. Cancer Res Commun. 2025. PMID: 39651931 Free PMC article. Clinical Trial.
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S; INTRIGUE investigators. Gelderblom H, et al. Among authors: razak aa. Eur J Cancer. 2023 Oct;192:113245. doi: 10.1016/j.ejca.2023.113245. Epub 2023 Jul 20. Eur J Cancer. 2023. PMID: 37598656 Free article. Clinical Trial.
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
Gelderblom H, Razak AA, Taylor MH, Bauer TM, Wilky B, Martin-Broto J, Gonzalez AF, Rutkowski P, Szostakowski B, Alcindor T, Saleh R, Genta S, Stacchiotti S, van de Sande M, Wagner AJ, Bernthal N, Davis LE, Vuky J, Tait C, Matin B, Narasimhan S, Sharma MG, Ruiz-Soto R, Sherman ML, Tap WD. Gelderblom H, et al. Among authors: razak aa. Clin Cancer Res. 2024 Sep 13;30(18):3996-4004. doi: 10.1158/1078-0432.CCR-24-0103. Clin Cancer Res. 2024. PMID: 38995311 Free PMC article. Clinical Trial.
90 results